Search Within

Jaclyn Frances Hechtman

  1. "David Ilson"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (9)
Groups
  1. Department of Medicine (20)
  2. Gastrointestinal Oncology Service (20)
  3. Hematologic Malignancies, Division of (20)
  4. Solid Tumor Oncology Division (20)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (19)
  6. Computational Oncology Service (19)

More Groups

People
  1. David Ilson (20)
  2. Geoffrey Ku (20)
  3. Yelena Janjigian (20)
  4. David Solit (19)
  5. Nikolaus Schultz (19)
  6. David Kelsen (15)

More People

Years
  1. 2023 (1)
  2. 2021 (3)
  3. 2020 (3)
  4. 2019 (7)
  5. 2018 (3)
  6. 2017 (1)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Clinical Cancer Research (3)
  3. Annals of Oncology (2)
  4. Cancer Discovery (2)
  5. Gastric Cancer (1)
  6. JAMA Network Open (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (5)
  3. Oxford University Press (3)
  4. American Medical Association (1)
  5. Elsevier Science, Inc. (1)
  6. Springer (1)

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Prevalence of germline alterations on targeted tumor-normal sequencing of esophagogastric cancer
    Journal Article

    Ku, G. Y.; Kemel, Y.; Maron, S. B.; Chou, J. F.; Ravichandran, V.; Shameer, Z.; Maio, A.; Won, E. S.; Kelsen, D. P.; Ilson, D. H.; more...
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset versus average-onset esophagogastric cancer
    Meeting Abstract

    Lumish, M. A.; Sabwa, S.; Maron, S. B.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; Joshi, S. S.; Gu, P.; Strong, V. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer
    Journal Article

    Moy, R. H.; Dos Santos Fernandes, G.; Jonsson, P.; Chou, J. F.; Basunia, A.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save